McKesson(US:MCK)2026-02-04 22:30Financial Performance - Revenues for the three months ended December 31, 2025, were $106,158 million, a 11.5% increase from $95,294 million in the same period of 2024[9] - Net income for the three months ended December 31, 2025, was $1,250 million, up 34.6% from $928 million in the same period of 2024[11] - Operating income for the nine months ended December 31, 2025, reached $4,062 million, a significant increase from $2,831 million in the same period of 2024[9] - Earnings per share (diluted) for the three months ended December 31, 2025, were $9.59, compared to $6.95 for the same period in 2024, reflecting a 37.5% increase[9] - Comprehensive income for the three months ended December 31, 2025, was $1,255 million, compared to $829 million in the same period of 2024[11] - Net income for the nine months ended December 31, 2025, was $3,244 million, an increase from $2,175 million in the same period of 2024, representing a growth of 49.2%[21] Assets and Liabilities - Total assets as of December 31, 2025, amounted to $84,190 million, an increase from $75,140 million as of March 31, 2025[15] - Cash and cash equivalents decreased to $2,959 million as of December 31, 2025, from $5,691 million as of March 31, 2025[15] - Total current liabilities increased to $68,131 million as of December 31, 2025, compared to $61,604 million as of March 31, 2025[15] - Goodwill increased to $11,324 million as of December 31, 2025, from $10,022 million as of March 31, 2025[15] - The company's long-term debt increased to $6,557 million as of December 31, 2025, up from $5,654 million as of March 31, 2025, representing a growth of 15.9%[96] Cash Flow and Dividends - Cash provided by operating activities for the nine months ended December 31, 2025, was $2,734 million, compared to cash used in operating activities of $(1,663) million in 2024[21] - The company declared cash dividends of $0.82 per common share during the three months ended December 31, 2025[17] - Cash dividends declared were $280 million, with a dividend per common share of $2.35[21] Acquisitions and Investments - The company made acquisitions totaling $3,412 million during the nine months ended December 31, 2025[21] - The Company acquired an 80% controlling interest in PRISM Vision Holdings for $875 million in cash, with an additional $25 million classified as redeemable noncontrolling interest[38] - The Company acquired a 70% controlling interest in Community Oncology Revitalization Enterprise Ventures for $2.5 billion in cash, with a total estimated fair value of consideration at $3.181 billion[43][47] Restructuring and Impairment - Restructuring, impairment, and related charges for the nine months ended December 31, 2025, totaled $146 million, compared to $276 million for the same period in 2024[54][59] - The Company anticipates total charges related to enterprise-wide initiatives to be between $650 million and $700 million, primarily for employee severance and related costs[55] - The company reported asset impairment charges of $10 million for the nine months ended December 31, 2025[21] Taxation - Income tax expense for the three months ended December 31, 2025, was $380 million, with a reported income tax rate of 23.3%, compared to $298 million and 24.3% for the same period in 2024[67] - During the nine months ended December 31, 2025, the company recognized a discrete tax benefit of $119 million related to the release of a valuation allowance in a foreign jurisdiction[69] Segment Performance - North American Pharmaceutical segment revenues increased to $88,322 million in Q3 2025 from $81,198 million in Q3 2024, representing a growth of 2.8%[198] - Oncology & Multispecialty segment revenues rose to $13,010 million in Q3 2025 compared to $9,493 million in Q3 2024, marking a significant increase of 37.7%[198] - The Medical-Surgical Solutions segment announced plans to separate into an independent company by May 8, 2025[193] Legal and Regulatory Matters - The Company has paid approximately $2.5 billion to settling governmental entities as of December 31, 2025, with an additional commitment of up to $5.4 billion through 2038[144] - The estimated total litigation liabilities for opioid-related claims as of December 31, 2025, amount to $5.708 billion, down from $6.377 billion as of March 31, 2025[154] - The Company is involved in ongoing litigation related to opioid distribution claims, with significant uncertainties regarding potential liabilities[143] Stock Repurchase and Dividends - The quarterly dividend was raised from $0.71 to $0.82 per share on July 29, 2025, with future dividends dependent on the Company's earnings and financial condition[165] - The Board authorized the repurchase of common stock, with the timing and number of shares repurchased depending on various factors including stock price and market conditions[166] - The total number of shares repurchased in Q1 2025 was 0.8 million at an average price of $709.84 per share, with a total dollar value of shares that may yet be purchased at $7,469 million[170]